TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33591016

Group type: EXPERIMENTAL
Intervention: Reduced mean cerebral tissue oxygen saturation during the first 12 hours of monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dose of cerebral tissue oxygen saturation desaturation
Number of subjects: 0
Study: 33591017

Group type: EXPERIMENTAL
Intervention: Highest normalized d-dimer level (≥ 8× the upper limit of normal)
Number of subjects: 3418
Study: 33591041

Group type: EXPERIMENTAL
Intervention: DMEK surgery
Number of subjects: 50
Study: 33591143

Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine with 20 μg of fentanyl
Number of subjects: 0
Study: 33591212

Group type: EXPERIMENTAL
Intervention: Dobutamine stress testing during catheterization
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Reduced-order model
Number of subjects: 21
Study: 33591291

Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions administered by a comfort coach
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study: 33591402

Group type: EXPERIMENTAL
Intervention: Standardized treatment for pediatric renal tumors (e.g., bilateral Wilms tumor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted and immune therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future trials
Number of subjects: 0
Study: 33591468

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg oral daily) plus trastuzumab (6 mg/kg intravenous every 21 days)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus trastuzumab
Number of subjects: 103
Study: 33591891

Group type: EXPERIMENTAL
Intervention: Emphysema progression at CT
Number of subjects: 0
Study: 33592103

Group type: EXPERIMENTAL
Intervention: Dapagliflozin for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 80
Study: 33592291

Group type: EXPERIMENTAL
Intervention: TA Treo device
Number of subjects: 46
Study: 33592838

Group type: EXPERIMENTAL
Intervention: Moxibustion applied to the Heart meridian
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moxibustion applied to the Lung meridian
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: COPD group (no intervention)
Number of subjects: 120
Study: 33592888

Group type: EXPERIMENTAL
Intervention: COVID-19-positive patients undergoing emergency digestive surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19-negative patients undergoing emergency digestive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cohort (patients from March to June 2019)
Number of subjects: 0
Study: 33593135

Group type: EXPERIMENTAL
Intervention: Sublingual tacrolimus 0.04 mg/kg/dose twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral tacrolimus (after sublingual administration)
Number of subjects: 10
Study: 33593311

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) and hypofractionated SBRT (5 fractions, total dose of 30 Gy with simultaneous integrated boost of 50 Gy on tumor-vessel interface) followed by IORT (10 Gy)
Number of subjects: 100
Study: 33593430

Group type: EXPERIMENTAL
Intervention: RBX2660 (one or two doses)
Number of subjects: 29
Study: 33593448

Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus monotherapy (every 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anti-vascular endothelial growth factor (VEGF) (monthly)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus monotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anti-vascular endothelial growth factor (VEGF)
Number of subjects: 40
Study: 33593763

Group type: EXPERIMENTAL
Intervention: Clinical characteristics, including demographics, pathology, treatment and prognosis of patients with GBC in China
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Adherence to clinical guidelines of GBC
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Improvement of clinical practice for diagnosing and treating GBC
Number of subjects: 6000
Study: 33593799

Group type: EXPERIMENTAL
Intervention: Penumbra SMART Coil System
Number of subjects: 851
Study: 33593867

Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) treatment
Number of subjects: 25
Study: 33593931

Group type: EXPERIMENTAL
Intervention: Multiple breath washout (MBW) using sulfur hexafluoride (SF6)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Age
Number of subjects: 100
Study: 33593940

Group type: EXPERIMENTAL
Intervention: Agonist-antagonist myoneural interfaces (AMIs) below-knee amputation (AB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional below-knee amputation (TB)
Number of subjects: 22
Study: 33593994

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC)
Number of subjects: 25551

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOAC)
Number of subjects: 25551

Group type: COMPARATOR
Intervention: NOAC
Number of subjects: 25551
Study: 33594075

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-OX40 (MEDI6469) therapy
Number of subjects: 17
Study: 33594224

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle GFAP concentrations in TBI patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Extracellular vesicle NfL concentrations in TBI patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 72
Study: 33594451

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Post-MT Parenchymal Hematoma (PH)
Number of subjects: 307
Study: 33594489

Group type: EXPERIMENTAL
Intervention: Subjects with cVFs (T7-T8 and T11-T12)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Subjects with lcVFs (T4-T6 and T9-T10)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Subjects with both cVFs and lcVFs
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Subjects without VFs
Number of subjects: 1237
Study: 33594602

Group type: EXPERIMENTAL
Intervention: CRLX301 at 75 mg/m2 Q3W
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CRLX301
Number of subjects: 42
Study: 33594934

Group type: EXPERIMENTAL
Intervention: Current practices and challenges in anal cancer screening for WLWH
Number of subjects: 25
Study: 33595110

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33595155

Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (10-100 mg/kg, twice daily, orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (100 mg/kg, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Number of subjects: 0
Study: 33595690

Group type: EXPERIMENTAL
Intervention: Trilaciclib at a dose of 240 mg/m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trilaciclib at a dose of ≥192 mg/m
Number of subjects: 0
Study: 33595733

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 501
Study: 33595793

Group type: EXPERIMENTAL
Intervention: PEGylated Asparaginase (PEG-ASNase) 2500 U/m2
Number of subjects: 1374

Group type: EXPERIMENTAL
Intervention: PopPK model
Number of subjects: 1374
Study: 33595899

Group type: EXPERIMENTAL
Intervention: Maternal dietary diversity score (DDS) in the highest quartile (diverse diets)
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Maternal dietary diversity score (DDS) in Quartile 1 (low dietary diversity)
Number of subjects: 3291
Study: 33596152

Group type: EXPERIMENTAL
Intervention: Diet and exercise habits (assessed with Healthy Eating Vital Signs and Stanford Brief Activity Survey)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Linear modelling
Number of subjects: 129
Study: 33596161

Group type: EXPERIMENTAL
Intervention: High-risk obstructive sleep apnea treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33596309

Group type: EXPERIMENTAL
Intervention: Fasting plasma GLP-1 concentrations in the obesity clinic group (median 3.3 pmol/L; interquartile range, 2.3-4.3 pmol/L)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Fasting GLP-1 concentrations
Number of subjects: 1978
Study: 33596668

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 viremia (detected in plasma from 48 (39%) patients at baseline)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Patients without viremia
Number of subjects: 123
Study: 33596867

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 225
Study: 33596889

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 epidemiology and public health measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological distress assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptoms assessment
Number of subjects: 0
Study: 33597012

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 2743
Study: 33597041

Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF) strategy
Number of subjects: 10
Study: 33597130

Group type: EXPERIMENTAL
Intervention: Assessment instruments used in the review
Number of subjects: 68
Study: 33597145

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (younger subgroup)
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (women)
Number of subjects: 11846

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (non-EU immigrants)
Number of subjects: 11846
Study: 33597152

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoid therapy, immunotherapies, and biologic therapy
Number of subjects: 18829

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 18829

Group type: EXPERIMENTAL
Intervention: People with IBD
Number of subjects: 18829

Group type: EXPERIMENTAL
Intervention: Mild lymphopenia and neutropenia in people with IBD
Number of subjects: 18829

Group type: COMPARATOR
Intervention: Mild lymphopenia and neutropenia in controls
Number of subjects: 18829
Study: 33597215

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity physical activity (MVPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of bout-related MVPA
Number of subjects: 0
Study: 33598307

Group type: EXPERIMENTAL
Intervention: Interactive telemedicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 33598309

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) and wrist-worn ActiGraph Link
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls via structured interview
Number of subjects: 40
Study: 33598473

Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33598475

Group type: EXPERIMENTAL
Intervention: Saffron extract (30 mg standardized saffron extract for 8 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33598552

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (target <140 mmHg <1 h)
Number of subjects: 3233

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering treatment (<180 mmHg)
Number of subjects: 3233
Study: 33598562

Group type: EXPERIMENTAL
Intervention: Thin slice computed tomography perfusion (CTP) images and cardiac computed tomography techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computed tomography-derived predictors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-processed thin-slice CTP images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imaging findings
Number of subjects: 0
Study: 33598844

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (group A: one oral hypoglycemic agent)
Number of subjects: 51
Study: 33598865

Group type: EXPERIMENTAL
Intervention: Active sacroiliitis on MRI
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatments
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 251

Group type: COMPARATOR
Intervention: Clinical experience model
Number of subjects: 251
Study: 33598905

Group type: EXPERIMENTAL
Intervention: CHICA-SUDEP module implementation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Before implementation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: After implementation
Number of subjects: 101
Study: 33598942

Group type: EXPERIMENTAL
Intervention: Bendamustine (30, 40, or 60 mg/m²) in combination with clofarabine, etoposide, and dexamethasone for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bendamustine (substituted for cyclophosphamide) in combination with clofarabine and etoposide
Number of subjects: 16
Study: 33598954

Group type: COMPARATOR
Intervention: No risk factors in men
Number of subjects: 30446

Group type: EXPERIMENTAL
Intervention: Six or more risk factors in men
Number of subjects: 30446

Group type: COMPARATOR
Intervention: No risk factors in women
Number of subjects: 30446

Group type: EXPERIMENTAL
Intervention: Six or more risk factors in women
Number of subjects: 30446
Study: 33599146

Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Number of subjects: 396
Study: 33599463

Group type: EXPERIMENTAL
Intervention: All-suture anchor dynamic anterior stabilization
Number of subjects: 3
Study: 33599735

Group type: EXPERIMENTAL
Intervention: Foveal pit depth and inner retinal layer (IRL) thickness measurements in extremely premature infants
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Comparison of foveal pit depth and IRL thickness over time
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Developmental displacement of the IRL
Number of subjects: 102
Study: 33599800

Group type: EXPERIMENTAL
Intervention: Diabetes patients hospitalised for COVID-19
Number of subjects: 2796
Study: 33599941

Group type: EXPERIMENTAL
Intervention: High-protein plant-based diet (~ 1.6 g kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Protein-matched omnivorous diet
Number of subjects: 19
Study: 33599951

Group type: EXPERIMENTAL
Intervention: UUI patients
Number of subjects: 10
Study: 33600102

Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples from patients with FA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples from patients with FH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intestinal mucosal samples for IgE antibody determination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of diagnostic methods
Number of subjects: 0
Study: 33600137

Group type: COMPARATOR
Intervention: Standard bleeding control course
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bleeding control course with addition of simulation and feedback device
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Retention testing 2 to 8 months later
Number of subjects: 66
Study: 33600210

Group type: EXPERIMENTAL
Intervention: Eprenetapopt plus Azacitidine (AZA)
Number of subjects: 52
Study: 33600745

Group type: EXPERIMENTAL
Intervention: Lumacaftor-Ivacaftor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33601050

Group type: EXPERIMENTAL
Intervention: Step count
Number of subjects: 0
Study: 33601057

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 11
Study: 33601960

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33602206

Group type: EXPERIMENTAL
Intervention: Clinical decision-support system (CDSS) for SIRS detection
Number of subjects: 168

Group type: COMPARATOR
Intervention: Physicians' SIRS recognition during clinical routine
Number of subjects: 168
Study: 33602254

Group type: EXPERIMENTAL
Intervention: FOPR test for HSN+SS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FOPR test for HSN-SS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FOPR test for healthy controls
Number of subjects: 63

Group type: COMPARATOR
Intervention: FOPR test
Number of subjects: 63
Study: 33602286

Group type: EXPERIMENTAL
Intervention: Intraarticular injection of umbilical cord-derived Wharton's Jelly (UC-derived WJ)
Number of subjects: 12
Study: 33602313

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections
Number of subjects: 30
Study: 33602316

Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) combined with CHOP (Bel-CHOP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) on Day 1-3 schedule
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m2) on Day 1-5 schedule
Number of subjects: 23
Study: 33602338

Group type: EXPERIMENTAL
Intervention: ABLE 1.0 intervention (8-week program)
Number of subjects: 30
Study: 33602357

Group type: EXPERIMENTAL
Intervention: Standard infant formula (SF)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Experimental infant formula (EF)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Formula fed groups (SF and EF)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Infant formula groups (SF and EF)
Number of subjects: 141
Study: 33602654

Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall upstaging
Number of subjects: 213
Study: 33602696

Group type: EXPERIMENTAL
Intervention: Hexatherapy regimen composed of adenovirus-based vaccine, IL-15 superagonist (N-803), anti-OX40, anti-4-1BB, anti-PD-L1, and docetaxel.
Number of subjects: 2
Study: 33602702

Group type: EXPERIMENTAL
Intervention: Sepsis Fast Track (SFT) programme
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Standard of care (non-exposed group)
Number of subjects: 3806
Study: 33602926

Group type: EXPERIMENTAL
Intervention: Standard TB therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Experimental TB treatment (did not reduce Mtb bacterial load)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 110
Study: 33603385

Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS)
Number of subjects: 44
Study: 33603496

Group type: EXPERIMENTAL
Intervention: Water vapor endometrial ablation
Number of subjects: 155
Study: 33603701

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Non-healthcare professionals (controls)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires at 6 weeks and 4 months
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Physical wellbeing assessment
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Variable provision of personal protection equipment
Number of subjects: 1050
Study: 33603710

Group type: EXPERIMENTAL
Intervention: Perturbation-Based Balance Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Intensive Balance Training
Number of subjects: 0
Study: 33604351

Group type: EXPERIMENTAL
Intervention: Plant-Based Diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animal-Based Diets
Number of subjects: 0
Study: 33604400

Group type: EXPERIMENTAL
Intervention: Convalescent COVID-19 plasma (CCP) treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Matched control group (no CCP available)
Number of subjects: 94
Study: 33604458

Group type: EXPERIMENTAL
Intervention: Concurrent paclitaxel-based chemoradiotherapy (CRT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Other modalities (Non-CRT)
Number of subjects: 57
Study: 33604486

Group type: EXPERIMENTAL
Intervention: Telehealth education program with tutor support (n = 178)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Telehealth education program without tutor support (Control group not explicitly mentioned)
Number of subjects: 326
Study: 33604802

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 280
Study: 33604947

Group type: EXPERIMENTAL
Intervention: Pancreatitis Activity Scoring System (PASS)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: PASS trajectories in mild AP
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Morphine equivalent dose
Number of subjects: 434
Study: 33604999

Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) enumeration and expression of PD-L1 and HLA-I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of CTC enumeration
Number of subjects: 0
Study: 33605440

Group type: COMPARATOR
Intervention: Behavioural support provided by dental professionals (one session)
Number of subjects: 14897

Group type: COMPARATOR
Intervention: Behavioural support combined with pharmacotherapy (e.g., nicotine replacement therapy or e-cigarettes)
Number of subjects: 14897

Group type: COMPARATOR
Intervention: Usual care, brief advice, very brief advice, or less active treatment
Number of subjects: 14897
Study: 33605445

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101; G) alone (G-mono)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) with fludarabine and cyclophosphamide (G-FC)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) with bendamustine (G-bendamustine)
Number of subjects: 971
Study: 33605465

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AHT) including β-blockers and/or ACE inhibitors
Number of subjects: 1425

Group type: COMPARATOR
Intervention: No antihypertensive treatment (Control)
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Patients with VIT treatment failure
Number of subjects: 1425
Study: 33605481

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Genotype GG+GA (rs1672717)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Longer duration of surgery
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control group (AA genotype)
Number of subjects: 407